Agency Forms Undergoing Paperwork Reduction Act Review, 33096-33097 [2013-12978]
Download as PDF
<![CDATA[
33096
Federal Register / Vol. 78, No. 106 / Monday, June 3, 2013 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Type of respondents
Study Salt Supplement Questionnaire .......................
75
Ron A. Otten,
Proposed Project
Director, Office of Scientific Integrity, Office
of the Associate Director for Science, Office
of the Director, Centers for Disease Control
and Prevention.
Spectrum of Flavoring ChemicalRelated Lung Disease—New—National
Institute for Occupational Safety and
Health (NIOSH), Centers for Disease
Control and Prevention (CDC).
[FR Doc. 2013–13038 Filed 5–31–13; 8:45 am]
BILLING CODE 4163–18–P
Background and Brief Description
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–13–13BF]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
chapter 35). To request a copy of these
requests, call (404) 639–7570 or send an
email to omb@cdc.gov. Send written
comments to CDC Desk Officer, Office of
Management and Budget, Washington,
DC 20503 or by fax to (202) 395–5806.
Written comments should be received
within 30 days of this notice.
Number of
responses per
respondent
Number of
respondents
Form name
This project involves a questionnaire,
along with clinical testing, to investigate
and characterize the nature of lung
disease occurring in popcorn and
flavoring workers. Since publication of
the 60-day Federal Register Notice, the
annual burden estimate has been
revised. We added the inclusion of job
and medication forms to be completed
by the participant prior to the testing
session. We also included the time
needed to review the informed consent.
The overall burden hours is now
estimated to be 115 hours.
The purpose of this study is to
investigate the spectrum of lung disease
occurring in flavoring and microwave
popcorn workers. A secondary aim is to
study the natural history of lung
disease. For this study, we plan on
interviewing and conducting clinical
testing on participants from a previously
investigated flavoring plant and
microwave popcorn plant.
For this study, we will recruit
participants from two study
populations: Approximately 112
Average burden
per response
(in hr)
3
5/60
workers from a flavorings plant for
whom we have spirometry data and 132
workers that had abnormal spirometry
on any test from a previous NIOSH
health hazard evaluation at a microwave
popcorn plant. Thirty additional
workers from the microwave popcorn
plant who had normal spirometry on
their last test also will be chosen at
random.
NIOSH anticipates that information
collection will begin in the 2013 fiscal
year for the microwave popcorn workers
and for the flavorings workers in fiscal
year 2014. Prior to the testing,
participants will be mailed a copy of the
informed consent to review and asked to
complete a job history form and current
medication form. This will take no more
than 25 minutes (total) to review and
complete. On the day of testing, a
NIOSH staff member will review the
consent form with the participant,
which will take about 5 minutes.
Participants will then be given a
NIOSH-administered questionnaire
which will take approximately 20
minutes to complete. All study results
will be stored at NIOSH.
Participation in all components of the
study is completely voluntary. There are
no costs to the respondents other than
their time. The total estimated annual
burden hours are 115.
ESTIMATED ANNUALIZED BURDEN HOURS
Form name
Popcorn workers ..............
Informed consent ........................................................
Medication form ..........................................................
Job history form ..........................................................
Questionnaire ..............................................................
Informed consent ........................................................
Medication form ..........................................................
Job history form ..........................................................
Questionnaire ..............................................................
sroberts on DSK5SPTVN1PROD with NOTICES
Flavoring workers .............
VerDate Mar<15>2010
18:49 May 31, 2013
Jkt 229001
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
Average
burden per
response
(in hours)
Number of
responses per
respondent
Number of
respondents
Type of respondents
81
81
81
81
56
56
56
56
E:\FR\FM\03JNN1.SGM
1
1
1
1
1
1
1
1
03JNN1
15/60
5/60
10/60
20/60
15/60
5/60
10/60
20/60
Federal Register / Vol. 78, No. 106 / Monday, June 3, 2013 / Notices
Ron A. Otten,
Director, Office of Scientific Integrity, Office
of the Associate Director for Science, Office
of the Director, Centers for Disease Control
and Prevention.
[FR Doc. 2013–12978 Filed 5–31–13; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[CDC–2013–0007; NIOSH–233]
NIOSH List of Antineoplastic and Other
Hazardous Drugs in Healthcare
Settings 2014: Proposed Additions and
Deletions to the NIOSH Hazardous
Drug List
National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS).
ACTION: Notice of Draft Document
Available for Public Comment.
AGENCY:
The National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC)
announces the availability of the
following draft document for public
comment entitled ‘‘NIOSH List of
Antineoplastic and Other Hazardous
Drugs in Healthcare Settings 2014:
Proposed Additions and Deletions to the
NIOSH Hazardous Drug List.’’ The
document and instructions for
submitting comments can be found at
https://www.regulations.gov.
This guidance document does not
have the force and effect of law.
Public Comment Period: Comments
must be received by August 2, 2013.
ADDRESSES: You may submit comments,
identified by CDC–2013–0007 and
Docket Number NIOSH–233, by either
of the two following methods:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: NIOSH Docket Office, Robert
A. Taft Laboratories, MS–C34, 4676
Columbia Parkway, Cincinnati, Ohio
45226.
Instructions: All information received
in response to this notice must include
the agency name and the docket number
(CDC–2003–0007; NIOSH–233). All
relevant comments received will be
posted without change to https://
www.regulations.gov, including any
personal information provided. All
electronic comments should be
sroberts on DSK5SPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
16:40 May 31, 2013
Jkt 229001
formatted as Microsoft Word. Please
make reference to CDC–2013–0007 and
Docket Number NIOSH–233.
SUPPLEMENTARY INFORMATION:
Background: The NIOSH Alert:
Preventing Occupational Exposures to
Antineoplastic and Other Hazardous
Drugs in Health Care Settings was
published in September 2004 (https://
www.cdc.gov/niosh/docs/2004-165/).
This Alert contained Appendix A which
was a list of drugs that were deemed to
be hazardous and may require special
handling. This list of hazardous drugs
was updated in 2010 and 2012 and
covered all new approved drugs and
drugs with new warning up to
December 2009. (https://www.cdc.gov/
niosh/docs/2010-167/; https://
www.cdc.gov/niosh/docs/2012-150/).
Between January 2010 and December
2011, 48 new drugs received FDA
approval and 276 drugs received special
warnings (usually black box warnings)
based on reported adverse effects in
patients. From this list of 324 drugs, 42
drugs were identified by NIOSH as
candidate hazardous drugs. Four of
these drugs had safe handling
recommendations from the
manufacturer and NIOSH is following
the recommendations of the
manufacturers. Therefore, these four
drugs will be listed as hazardous
without requiring further review. A
panel consisting of peer reviewers and
stakeholders was asked to review and
comment on the remaining 38
potentially hazardous drugs. In
addition, the panel members were asked
to comment on the addition of one drug
requested by several stakeholders and
the removal of one drug from the 2012
Hazardous Drug List. Reviewers were
not asked to provide a consensus
opinion and NIOSH made the final
determination regarding additions and
deletions to the 2014 hazardous drug
list.
NIOSH reviewed the
recommendations of the peer reviewers
and stakeholders and determined that
24 drugs in addition to the 4 drugs with
manufacturer’s warnings, were
determined to have one or more
characteristics of a hazardous drug and
this list of 28 drugs is being published
for comment in CDC–2013–0007 and
NIOSH Docket Number 233. In addition,
1 drug from the 2012 Hazardous Drug
List is being considered for removal.
The complete list of these drugs can be
found at: https://www.regulations.gov as
a supporting document.
FOR FURTHER INFORMATION CONTACT:
Barbara MacKenzie, NIOSH, Robert A.
Taft Laboratories, 4676 Columbia
Parkway, MS–C26, Cincinnati, Ohio
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
33097
45226, telephone (513) 533–8132, Email
hazardousdrugs@cdc.gov.
Dated: May 24, 2013.
John Howard,
Director, National Institute for Occupational
Safety and Health, Centers for Disease Control
and Prevention.
[FR Doc. 2013–13043 Filed 5–31–13; 8:45 am]
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Agency Information Collection
Activities; Proposed Collection;
Comment Request: Generic Clearance
for the Collection of Qualitative
Feedback on Agency Service Delivery,
National Institute of Neurological
Disorders and Stroke (NINDS)
As part of a Federal
Government-wide effort to streamline
the process to seek feedback from the
public on service delivery, the National
Institute of Neurological Disorders
(NINDS) has submitted a Generic
Information Collection Request (Generic
ICR): ‘‘Generic Clearance for the
Collection of Qualitative Feedback on
Agency Service Delivery’’ to OMB for
approval under the Paperwork
Reduction Act (PRA) (44 U.S.C. 3501 et.
seq.).
DATES: Comments must be submitted
within 30 days after publication in the
Federal Register.
ADDRESSES: Written comments may be
submitted to the Office of Management
and Budget, Office of Information and
Regulatory Affairs, Attn: NIH Desk
Officer, by Email to
OIRA_submission@omb.eop.gov, or by
fax to 202–395–6974.
FOR FURTHER INFORMATION CONTACT: To
request additional information, please
contact: Paul Scott, Ph.D., Director,
Office of Science Policy and Planning,
NINDS, 31/8A03 Center Drive,
Bethesda, MD 20892–2178, or Email
your request, including your address to
scottp@ninds.nih.gov.
SUPPLEMENTARY INFORMATION:
Title: Generic Clearance for the
Collection of Qualitative Feedback on
Agency Service Delivery.
Abstract: The information collection
activity will garner qualitative customer
and stakeholder feedback in an efficient,
timely manner, in accordance with the
Administration’s commitment to
improving service delivery. By
qualitative feedback we mean
information that provides useful
insights on perceptions and opinions,
SUMMARY:
E:\FR\FM\03JNN1.SGM
03JNN1
]]>Agencies
[Federal Register Volume 78, Number 106 (Monday, June 3, 2013)]
[Notices]
[Pages 33096-33097]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-12978]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-13-13BF]
Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention (CDC) publishes a
list of information collection requests under review by the Office of
Management and Budget (OMB) in compliance with the Paperwork Reduction
Act (44 U.S.C. chapter 35). To request a copy of these requests, call
(404) 639-7570 or send an email to omb@cdc.gov. Send written comments
to CDC Desk Officer, Office of Management and Budget, Washington, DC
20503 or by fax to (202) 395-5806. Written comments should be received
within 30 days of this notice.
Proposed Project
Spectrum of Flavoring Chemical-Related Lung Disease--New--National
Institute for Occupational Safety and Health (NIOSH), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
This project involves a questionnaire, along with clinical testing,
to investigate and characterize the nature of lung disease occurring in
popcorn and flavoring workers. Since publication of the 60-day Federal
Register Notice, the annual burden estimate has been revised. We added
the inclusion of job and medication forms to be completed by the
participant prior to the testing session. We also included the time
needed to review the informed consent. The overall burden hours is now
estimated to be 115 hours.
The purpose of this study is to investigate the spectrum of lung
disease occurring in flavoring and microwave popcorn workers. A
secondary aim is to study the natural history of lung disease. For this
study, we plan on interviewing and conducting clinical testing on
participants from a previously investigated flavoring plant and
microwave popcorn plant.
For this study, we will recruit participants from two study
populations: Approximately 112 workers from a flavorings plant for whom
we have spirometry data and 132 workers that had abnormal spirometry on
any test from a previous NIOSH health hazard evaluation at a microwave
popcorn plant. Thirty additional workers from the microwave popcorn
plant who had normal spirometry on their last test also will be chosen
at random.
NIOSH anticipates that information collection will begin in the
2013 fiscal year for the microwave popcorn workers and for the
flavorings workers in fiscal year 2014. Prior to the testing,
participants will be mailed a copy of the informed consent to review
and asked to complete a job history form and current medication form.
This will take no more than 25 minutes (total) to review and complete.
On the day of testing, a NIOSH staff member will review the consent
form with the participant, which will take about 5 minutes.
Participants will then be given a NIOSH-administered questionnaire
which will take approximately 20 minutes to complete. All study results
will be stored at NIOSH.
Participation in all components of the study is completely
voluntary. There are no costs to the respondents other than their time.
The total estimated annual burden hours are 115.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response (in
respondents respondent hours)
----------------------------------------------------------------------------------------------------------------
Popcorn workers.................. Informed consent.... 81 1 15/60
Medication form..... 81 1 5/60
Job history form.... 81 1 10/60
Questionnaire....... 81 1 20/60
Flavoring workers................ Informed consent.... 56 1 15/60
Medication form..... 56 1 5/60
Job history form.... 56 1 10/60
Questionnaire....... 56 1 20/60
----------------------------------------------------------------------------------------------------------------
[[Page 33097]]
Ron A. Otten,
Director, Office of Scientific Integrity, Office of the Associate
Director for Science, Office of the Director, Centers for Disease
Control and Prevention.
[FR Doc. 2013-12978 Filed 5-31-13; 8:45 am]
BILLING CODE 4163-18-P
